HOW DID WE GET HERE? Heart failure guidelines are based around inhibition of the renin-
angiotensin and sympathetic nervous systems, two fundamental pathways which drive the …

Aims We systematically reviewed the European real‐world evidence (RWE) about sacubitril‐
valsartan for heart failure with reduced ejection fraction. Methods and results Twenty‐one …

The change in Gibbs energy when an ion or molecule moves from a vacuum to a solvent is
known as solvation energy and solvation is the process of attracting and associating …

Cardiovascular diseases have become a major clinical burden globally. Heart failure is one
of the diseases that commonly emanates from progressive uncontrolled hypertension. This …

Sacubitril/Valsartan (S/V) carries potential anti-remodeling properties, however long-term
effects and biventricular adaptive response are poorly described. 76 HFrEF patients who …

Objective Cardiac diastolic dysfunction (DD) and arterial stiffness are early manifestations of
obesity-associated prediabetes, and both serve as risk factors for the development of heart …

Background Sacubitril/valsartan reduces mortality in patients with heart failure with reduced
ejection fraction (HFrEF) when compared with enalapril. However, it is unknown the effect of …

Background: right ventricle-pulmonary artery (RV-PA) coupling assessed by measuring the
tricuspid anular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) …

Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular
mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced …

The Prospective comparison of ARNI with angiotensin-converting enzyme inhibitor to
Determine Impact on Global Mortality and morbidity in Heart Failure trial identified a marked …